Uglianitsa K N, Nechiporenko N A, Nefyodov L I, Brzosko W J
Oncology Department of Grodno Medical School, Belarus.
Drugs Exp Clin Res. 1998;24(5-6):227-30.
The aim of the present study was to evaluate the efficacy of Ukrain as a new treatment modality in 28 patients with stage T1N0M0 bladder cancer. The tumor dimensions varied from 0.5 x 0.5 cm to 3 x 4 cm. The first group (nine patients) was treated with a total dose of 100 mg Ukrain, the second group (10 patients) received 200 mg Ukrain, and the third group (nine patients) was treated with 300 mg Ukrain. In all patients Ukrain was administered i.v. at a dose of 10 mg per day. In the patients from the second and third group each course of treatment, consisting of 10 injections, was followed by 14 days of no treatment. Ukrain, at a total dose from 100-300 mg as neoadjuvant therapy in patients with T1N0M0 bladder cancer, resulted in either complete or partial regression of tumors in 60.7 +/- 9.2% of cases. The best treatment regime included three courses of Ukrain at 2-week intervals.
本研究的目的是评估乌头碱作为一种新的治疗方式对28例T1N0M0期膀胱癌患者的疗效。肿瘤大小从0.5×0.5厘米到3×4厘米不等。第一组（9例患者）接受了100毫克乌头碱的总剂量治疗，第二组（10例患者）接受了200毫克乌头碱，第三组（9例患者）接受了300毫克乌头碱治疗。所有患者均通过静脉注射给予乌头碱，剂量为每天10毫克。第二组和第三组患者的每个疗程由10次注射组成，随后有14天不进行治疗。乌头碱总剂量为100 - 300毫克，作为T1N0M0期膀胱癌患者的新辅助治疗，在60.7 +/- 9.2%的病例中导致肿瘤完全或部分消退。最佳治疗方案包括每隔2周进行三个疗程的乌头碱治疗。
